TCEAL3 (WEX8) as a Drug Target and Biomarker: Implications for Neurodegenerative Disorders

Target Name: TCEAL3

NCBI ID: G85012

TCEAL3

TCEAL3 (WEX8) as a Drug Target and Biomarker: Implications for Neurodegenerative Disorders

Abstract:
TCEAL3 (WEX8) is a unique protein that has been identified as a potential drug target and biomarker for neurodegenerative disorders. Its expression has been observed in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This protein has been shown to play a crucial role in the development and progression of these diseases, making it an attractive target for drug development. Additionally, TCEAL3 has also been found to be a potential biomarker for these disorders, with its levels declining in the affected brain.

Introduction:
Neurodegenerative diseases are a group of disorders that affect the brain and nervous system, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and other forms of dementia. These disorders are characterized by progressive cognitive and motor function decline, as well as the loss of brain cells. Despite the efforts in research, the treatment options for these disorders are limited, and there is a high demand for new and effective drugs that can slow down or even reverse the progression of these diseases.

TCEAL3 as a Drug Target:
TCEAL3 (WEX8) is a protein that has been shown to play a crucial role in the development and progression of neurodegenerative diseases. Its expression has been observed in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, TCEAL3 has been shown to be involved in the formation of neurofibrillary tangles and beta-amyloid plaques, which are hallmark hallmarks of neurodegenerative diseases.

The potential drug target for TCEAL3 is the neurodegenerative diseases, specifically those that are characterized by the formation of neurofibrillary tangles and beta-amyloid plaques. These drugs can target the formation of these tangles and plaques, which can slow down or even reverse the progression of the diseases. Additionally, TCEAL3 has also been shown to play a role in the regulation of the immune response, which is a crucial aspect of neurodegenerative diseases.

TCEAL3 as a Biomarker:
TCEAL3 (WEX8) has also been found to be a potential biomarker for neurodegenerative diseases. The levels of TCEAL3 have been found to be declining in the affected brain, which could indicate the early stages of neurodegenerative diseases. Additionally, TCEAL3 has been shown to be involved in the regulation of the lifespan of neural stem cells, which are crucial for the development and maintenance of the nervous system.

Conclusion:
TCEAL3 (WEX8) is a unique protein that has been identified as a potential drug target and biomarker for neurodegenerative disorders. Its expression has been observed in various neurodegenerative diseases, and its potential as a drug target and biomarker makes it an attractive target for further research. Additionally, the decline in TCEAL3 levels in the affected brain could indicate the early stages of neurodegenerative diseases, making it an even more promising target for drug development.

Protein Name: Transcription Elongation Factor A Like 3

Functions: May be involved in transcriptional regulation

The "TCEAL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TCEAL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets